Sign up Australia
Proactive Investors - Run By Investors For Investors

ImpediMed begins lymphoedema study using its health device

The aim is to detect lymphoedema at the earliest possible point.
ImpediMed begins lymphoedema study using its health device
Accurate measurement allows early detection and intervention

ImpediMed (ASX:IPD) has commenced enrolment in the first planned clinical study of its “SOZO” device for lymphoedema, a condition that causes swelling in the body's tissues.

SOZO uses bioimpedance spectroscopy (BIS) technology to manage and monitor a person’s fluid status, body composition and hydration in a clinical or at-home setting.

Lymphoedema is a leading post-surgical complication for many breast cancer patients and significantly impacts quality of life.

The accurate measurement of fluid in limbs by SOZO allows early detection and intervention.

Importantly, the aim of this study is to determine the best practices for at-home lymphoedema monitoring.

The study is being led by Louise Koelmeyer, the Lymphoedema Program Manager of Macquarie University Hospital’s ALERT (Australian Lymphoedema Education, Research & Treatment) program.

The ALERT team aims to optimise positive outcomes for people living with lymphoedema through excellence in assessment and management of the condition along the continuum.

Macquarie University has recognised the potential for SOZO to improve the way patients are monitored and has initiated this study to help establish how the at-home program is best implemented.

The aim is to detect lymphoedema at the earliest possible point in its development when its progression can be stopped or even reversed.

View full IPD profile View Profile

ImpediMed Timeline

November 14 2013

Related Articles

woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use